Cargando…

Clarification of Linaclotide Pharmacology Presented in a Recent Clinical Study of Plecanatide

Detalles Bibliográficos
Autores principales:	Busby, Robert W., Ortiz, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991828/ https://www.ncbi.nlm.nih.gov/pubmed/24652108 http://dx.doi.org/10.1007/s10620-013-2953-x

Ejemplares similares

Clinical utility of plecanatide in the treatment of chronic idiopathic constipation
por: Islam, Bianca N, et al.
Publicado: (2018)

Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation
por: DeMicco, Michael, et al.
Publicado: (2017)

Improving the Gastrointestinal Stability of Linaclotide
por: Braga Emidio, Nayara, et al.
Publicado: (2021)

Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide
por: Rao, Satish S.C., et al.
Publicado: (2023)

The fetuses-at-risk approach: Clarification of semantic and conceptual misapprehension
por: Joseph, K S
Publicado: (2008)

Placenta Previa Accreta and Previous Cesarean Section: Some Clarifications
por: Matsubara, Shigeki, et al.
Publicado: (2018)

The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: A clarification of its content
por: Mokkink, Lidwine B, et al.
Publicado: (2010)

Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation
por: Rao, Satish S.C.
Publicado: (2018)

Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy
por: Sharma, Amol, et al.
Publicado: (2019)

Therapeutically targeting guanylate cyclase‐C: computational modeling of plecanatide, a uroguanylin analog
por: Brancale, Andrea, et al.
Publicado: (2017)

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
por: Miner Jr, Philip B, et al.
Publicado: (2017)

Children Born to HIV-Infected Mothers in Côte d'Ivoire: Methodological Clarifications Needed
por: Sarr, Moussa
Publicado: (2007)

Quantitative survey into value clarification of discussed treatment options among patients treated for basal cell carcinoma
por: van Delft, L.C.J., et al.
Publicado: (2019)

Correction/Clarification about FDA Review Documents
por: Turner, Erick
Publicado: (2005)

A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide
por: Qiu, Zhonghao, et al.
Publicado: (2023)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
por: Dein, Eric J., et al.
Publicado: (2021)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

Randomised clinical trial: linaclotide vs placebo—a study of bi‐directional gut and brain axis
por: Rao, Satish S.C., et al.
Publicado: (2020)

Linaclotide-induced electrolyte secretion in human and rat colon: Ussing chamber studies
por: Tchernychev, Boris, et al.
Publicado: (2015)

Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models
por: Boulete, Illona-Marie, et al.
Publicado: (2018)

Linaclotide induces secretion of cGMP from mouse colonic epithelium
por: Tchernychev, Boris, et al.
Publicado: (2013)

Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold
por: Cobos, Claudia, et al.
Publicado: (2018)

Emphasis on rigorous standards - clarification on recent retraction notice
por: Lee, Younsuk
Publicado: (2023)

Linaclotide utilization and potential for off-label use and misuse in three European countries
por: Cid-Ruzafa, Javier, et al.
Publicado: (2022)

Clarification
Publicado: (2007)

Clarification
Publicado: (2009)

Clarification
Publicado: (2013)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc(+/Min-FCCC) mice
por: Chang, Wen-Chi L, et al.
Publicado: (2017)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

Recent Developments of Membrane Technology in the Clarification and Concentration of Fruit Juices
por: Sarbatly, Rosalam, et al.
Publicado: (2023)

Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials
por: Brenner, Darren M, et al.
Publicado: (2023)

Corrections and Clarifications
Publicado: (2000)

Corrections and Clarifications
Publicado: (2000)

Corrections and Clarifications
Publicado: (2000)

Corrections and Clarifications
Publicado: (2000)

Corrections and Clarifications
Publicado: (2002)

Corrections and Clarifications
Publicado: (1997)

Corrections and Clarifications
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_d7i1aom0jn7hg4t8kfdckje0qq